TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Tampa Scale for Kinesiophobia-11
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cortisol chronic tissue impregnation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference of hs-cTnT concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment efficacy assessed by parents' mood (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment efficacy assessed by parents' anxiety [Spielberger State-Trait Anxiety (STAI, state scale)]
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child-Behavioral Emotional Functioning: Anxious/Depressed score on CBCL
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in QT Interval Corrected for Heart Rate (QTc) for BIIB091
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in QT Interval Corrected for Heart Rate (QTc) for Metabolite 23 (M23)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of Guselkumab
Endpoint domain: Adverse events/effects
Primary endpoint: Participant assessment scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma diclofenac concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fold-change increase in CD27/CD28 double positive T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in trunk stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Interpolated Twitch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Single Leg Stand (SLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Single Leg Land and Hold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported Pain Intensity Score of 0 or 1
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Achieving EASI-75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Markers of systemic immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in trust from baseline to 4 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety in home setting at 4 months
Endpoint domain: Adverse events/effects
Primary endpoint: Safety in community setting at 4 months
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of Lipopolysaccharide (LPS) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of patients with hypotension event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non-inferiority of single fraction radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful uncomplicated PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantitative questionnaire 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: lesion volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: microglial activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinically significant changes from baseline in clinical laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant changes from baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant changes from baseline in cardiac conduction intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NPI-12 total score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of Participants With Hemoglobin (Hb) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Participants With Transfusion Independence During the Core Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Participants With Transfusion Independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with skeletal-related events (SREs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum rhTPO concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement Rate of Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intervention Satisfaction Questionnaire Mean Score Group A
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intervention Satisfaction Questionnaire Mean Score Group B
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in peak FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percent of cured tuberculous patients
Endpoint domain: Mortality/survival
Primary endpoint: percent of treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of depth estimation by difference in attenuation from opposing views
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of depth estimation by difference in apparent lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of depth estimation by triangulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Care Self-Efficacy Scale (SCSE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The EuroQoL-5-D instruments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Family Assessment Device Questionnaire - Global Family Function Subscale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of LY3537982
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY3537982
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in RBC transfusion burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in mean hemoglobin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants achieving IGA-CHE-TS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Michigan Neuropathy Screening Instrument
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Annualised rate of severe COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Iberdomide Pharmacokinetics - AUC(0-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolite M12 Pharmacokinetics - AUC(0-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iberdomide Pharmacokinetics - Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of circulating HPV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dental scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute change in spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of submental fat thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on MACE+ events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentration of Daclatasvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of Sofosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of completed sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants satisfied with the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: One year risk mortality
Endpoint domain: Mortality/survival
Primary endpoint: Influenza or COVID-19 antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymph node diagnosis (benign or malignant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ratio of UACR levels at 6 months to baseline UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain Score (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient-reported Demoralization Scale-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Blood Viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Treatment efficacy according to response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine albumin creatinine ratio (uACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hemodialysis Comfort Scale Version-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to first symptom of treatment failure (TFST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of TBP in Plasma and Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC) Extrapolated to Infinity [AUC(0-inf)] of TBP in Plasma and Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of TBP in Plasma and Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of ReHandyBot
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of the clinical staff supporting therapy with ReHandyBot
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of supervised therapy sessions with ReHandyBot
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Epinephrine response during hypoglycemic clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 1 year Event-free Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants that complete the program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CR-SMFRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PR-SMFRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of all-cause death, stroke, MI, unplanned revascularization, LVAD implant, heart transplant, or CV hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of myopotential interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evaluation of distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: evaluation of current anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: evaluation of anxiety state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 4-day biofilm accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 1 year Disease-Free Survival (DFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Ankle Osteoarthritis Scale (AOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of adherence of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of breastfeeding education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participant Intervention Completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma AUCinf after administration of the FC formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax after administration of the FC formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUClast after administration of the FC formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fundus photo image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6-minute-walk-test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plantar-flexor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Coma Recovery Scale-Revised (CRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rappaport Coma/Near Coma Scale (CNCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Coma Recovery Scale for Pediatrics (CRS-P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence and severity of paclitaxel-induced peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Damage of nerve fibers induced by paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevention of relapse among patients with Alcohol Use Disorders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change from Baseline in Depression Scores on the CES-D
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change from Baseline in Impulsiveness Scores on the BIS-11
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Change from Baseline in Movement Scores on Part III of the MDS-UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of individuals screening positive for SCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonoscopy uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Up-to-date CRC screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Peripheral and brain immune activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-COVID-19 symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection Rate of Psoriatic Arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of Smart Phone Application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-reported hot flash scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Bohr dead space ventilation (VDBr/VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in UE-FMA at the end of the training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UE-FMA at 90 days post training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UE-FMA at 6 months post stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Subjective Stress Experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Short-Term Neuroendocrine Stress: Hypothalamic-Pituitary-Adrenal Axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Short-Term Neuroendocrine Stress: Autonomic Nervous System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acceptability: CTS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability: CSQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptability: Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness: PARDI-AR-Q
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness: FNS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient knowledge of individual waitlist status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in frequency of shared decision-making conversations
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in donor kidney preferences
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: peak neuron-specific enolase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: response to diuretic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of central line associated bloodstream infections (CLABSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate of [18F]PSMA-1007
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the anti-adhesion activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pad use for urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of erectile dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: weekly body weight measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDEQ Global Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Loss of Asthma Control event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total clearance rate of treated CW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Mevrometostat (Formulation 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Mevrometostat (Formulation 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Mevrometostat (Formulation 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Mevrometostat (Formulation 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infants with at least a 4-fold increase in anti-serotype-specific Shigella LPS/OAg serum IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Net Lumen Gain (NLG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Household Preparedness Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Household Preparedness Matrix
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relative ligament thickness of the UCL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the ulnohumeral joint laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute abundance of gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fold change in relative abundance of gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in One Repetition Maximum Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hip extension Range of motion in degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Pediatric Berg Balance Scale (PBBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of cases to develop OHSS
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of lonca-R
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative analgesic doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPSR (Numeric Pain Scale Rating)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Learning ability: skill learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Learning ability: Explicit memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning